Quality of life and outcomes in patients undergoing endoscopic papillectomy vs surgical treatment for duodenal papillary adenomas

doi:10.4240/wjgs.v17.i6.106637

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (136)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-5) series.

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-5)

Sum=96

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=34

Jun 27, 2025 (publication date) through Jun 2, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Surg. Jun 27, 2025; 17(6): 106637
Published online Jun 27, 2025. doi: 10.4240/wjgs.v17.i6.106637

Table 1 Demographics, baseline characteristics, risk factors, and clinical profile at the time of duodenal papillary adenoma diagnosis based on availability of long-term follow-up, mean ± SD/n (%)

Variable	EP (n = 155)	Surgery (n = 43)	P value
Age, years			0.051
mean ± SD	56.9 ± 10.4	60.1 ± 8.68
Range	28-81	39-75
≤ 39	7 (4.5)	1 (2.3)
40-49	29 (18.7)	3 (7.0)
50-59	60 (38.7)	17 (39.5)
60-69	43 (27.7)	16 (37.2)
≥ 70	16 (10.3)	6 (14.0)
Sex			0.162
Female	54 (38.4)	20 (46.5)
Male	101 (65.2)	23 (53.5)
BMI (kg/m²)			0.001
Normal/low (≤ 23.9)	74 (47.7)	33 (76.7)
Overweight (24-27.9)	66 (42.6)	9 (20.9)
Obese (≥ 28)	15 (9.7)	1 (2.3)
Comorbidities
History of hypertension	63 (40.6)	17 (39.5)	0.896
History of diabetes	26 (16.8)	8 (18.6)	0.778
History of hyperlipidemia	36 (23.2)	4 (9.3)	0.053
History of heart disease	27 (17.4)	3 (7.0)	0.195
History of liver disease	38 (24.5)	13 (30.2)	0.448
History of renal disease	31 (20.0)	10 (23.3)	0.641
History of other tumors	20 (12.9)	5 (11.6)	0.824
History of stroke	4 (2.6)	1 (2.3)	1.000
Current smoking	26 (16.8)	4 (9.3)	0.227
Current alcohol consumption	11 (7.1)	2 (4.7)	0.822
CEA (ng/mL), median (IQR)	1.0 (0.5-1.6)	1.1 (0.6-1.9)	0.299
CA-199 (U/mL), median (IQR)	9.5 (5.8-12.5)	15.0 (9.6-26.6)	< 0.001
TBil (μmol/L), median (IQR)	10.5 (7.1-13.7)	11.5 (9.0-15.8)	0.138
DBil (μmol/L), median (IQR)	2.4 (1.8-3.5)	3.1 (2.1-4.9)	0.020
ALT (U/L), median (IQR)	16.5 (12.6-22.4)	18.8 (11.7-56.0)	0.090
ALP (U/L), median (IQR)	66.7 (55.8-85.0)	74.4 (64.2-144.3)	0.003
GGT (U/L), median (IQR)	20.9 (15.9-30.7)	25.4 (19.2-459.6)	0.001
Hb (g/L), median (IQR)	137.0 (126.0-150.0)	128.0 (117.0-136.0)	< 0.001
WBC (× 10⁹/L), median (IQR)	5.1 (4.4-6.3)	5.2 (4.1-6.6)	0.942
PLT (× 10⁹/L), median (IQR)	186.0 (157.0-215.0)	201.0 (177.0-234.0)	0.029

EP: Endoscopic papillectomy; BMI: Body mass index; CEA: Carcinoembryonic antigen; CA-199: Carcinoma antigen-199; TBil: Total bilirubin; DBil: Direct bilirubin; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; GGT: Gamma-glutamyl transferase; Hb: Hemoglobin; WBC: White blood cells; PLT: Platelets.

Citation: Wang FL, Tang XX, Wu R, Gao YJ, Liu YR, Wang L, Zou XP, Zhang B. Quality of life and outcomes in patients undergoing endoscopic papillectomy vs surgical treatment for duodenal papillary adenomas. World J Gastrointest Surg 2025; 17(6): 106637
URL: https://www.wjgnet.com/1948-9366/full/v17/i6/106637.htm
DOI: https://dx.doi.org/10.4240/wjgs.v17.i6.106637